PCM
MRSN

Prelude Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Prelude Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,054
Closed -$73.4K – 1413
2024
Q4 		$73.4K Sell
2,054
-12,535
-86% -$648K ﹤0.01% 1126
2024
Q3 		$689K Buy
+14,589
New +$644K 0.04% 503
2020
Q4 		– Sell
-18
Closed -$8K – 1724
2020
Q3 		$8K Buy
+18
New +$9.1K ﹤0.01% 1490
2018
Q2 		– Sell
-90
Closed -$36K – 1837
2018
Q1 		$36K Buy
90
+86
+2,150% +$34K ﹤0.01% 1160
2017
Q4 		$2K Buy
+4
New +$1.74K ﹤0.01% 1300

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Prelude Capital Management's MRSN Position: Q1 2025 in Review

Prelude Capital Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 2,054 shares — an estimated $73.4K sold.

Prelude Capital Management first reported a position in MRSN in Q4 2017 and held it in 5 quarters. The position peaked at $689K in Q3 2024. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Prelude Capital Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 2,054 Mersana Therapeutics shares in Q1 2025, an estimated $73.4K.
  • Prelude Capital Management first reported a position in Mersana Therapeutics in Q4 2017 and held it in 5 quarters.
  • Prelude Capital Management's Mersana Therapeutics position peaked at $689K in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.